Ask Warren

Protia

303360 · KOSDAQ · ₩303360 · 프로티아

₩3,650▲ ₩100 (2.82%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +17.57%
Market cap
₩47B
Enterprise value
₩45B
P/E
9.0×
P/B
1.4×
Dividend yield
0.0%
ROE
15.8%
Net margin
29.5%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−20.6% from the high

₩2,454Today: ₩3,560 – ₩3,655₩4,595

Returns

  • 1W−3.1%
  • 1M+2.1%
  • 3M+10.7%
  • 6M+9.7%
  • YTD−12.3%
  • 1Y+17.6%
Volume today
6,703
0.1× the 20-day average
Traded today
₩24M
Listed shares
12,879,715
EPS (12 months)
₩406
Earnings yield 11.1%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

26Quiet
  • BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
  • MomentumFlat2.7% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Protia stock overview

Protia (프로티아, KRX: 303360) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops, manufactures and sells in vitro diagnostic medical devices based on immunodiagnostic core technology. Its shares closed at ₩3,650 on Oct 27, 2026, up 2.82% on the day, giving it a market value of ₩47B.

Key facts

Market cap
₩47B
Sector
Medical & precision devices
Latest price change
+2.82%
As of
Oct 27, 2026
Main business
The company develops, manufactures and sells in vitro diagnostic medical devices based on immunodiagnostic core technology.

Quick answers about Protia

What does Protia do?
The company develops, manufactures and sells in vitro diagnostic medical devices based on immunodiagnostic core technology. Its main products are allergy diagnostic kits and analyzers for humans and animals, along with food intolerance, autoimmune, antibiotic susceptibility and rapid point-of-care tests. It sells domestically through distributors to large medical foundations and general hospitals, and overseas through local distributors in about 80 countries.
What is the market cap of Protia?
The market capitalisation of Protia was ₩47B at the close on Oct 27, 2026.
Who are the largest shareholders of Protia?
According to the latest official filings, the largest reported holders are Im Guk-jin (42.72%, as of Nov 27, 2024); Im Jin-hyung (0.39%, as of Apr 10, 2026); Choi Dong-seop (0.39%, as of Apr 8, 2026).
When is the next earnings report from Protia?
Korean companies rarely announce results dates in advance. Based on when Protia filed the same report in past years, its next 3q results is expected between Nov 6, 2026 and Nov 14, 2026.

Company profile

The company develops, manufactures and sells in vitro diagnostic medical devices based on immunodiagnostic core technology. Its main products are allergy diagnostic kits and analyzers for humans and animals, along with food intolerance, autoimmune, antibiotic susceptibility and rapid point-of-care tests. It sells domestically through distributors to large medical foundations and general hospitals, and overseas through local distributors in about 80 countries.

Written by AI from the company's latest annual report.

Korean name
프로티아
Sector
Medical & precision devices
Themes
Medical devices
CEO
임국진
Founded
Mar 2000
Listed
Jun 2023
Listed shares
12,879,715
Fiscal year ends
Month 12
Website
www.protia.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Protia / 프로티아 / 303360 / KRX:303360

Source: KRX statistical information